Maxim’s healthcare analyst Jason Kolbert reiterated coverage on the clinical-stage biopharmaceutical company Anavex Life Sciences Corp. (NASDAQ:AVXL) and cell therapy company Cytori Therapeutics Inc (NASDAQ:CYTX). Lets take a look and see what Kolbert has to say about AVXL and CYTX.

Anavex Life Sciences Corp.

Kolbert reiterated a Buy rating on shares of Anavex Life Sciences, with a price target of $15, after the company announced that it is moving forward with the development program for ANAVEX 2-73, a candidate drug for Parkinson’s disease. Furthermore, the company announced the appointment of Ulrich Elben, PhD as Vice President of Preclinical Operations.

The analyst noted, “Guidance received from the FDA confirms the strategy to advance ANAVEX 2-73 (Alzheimer’s) in a larger double-blinded, randomized, placebo-controlled P 2/3 study. Recall that Anavex just last week presented data at the International Clinical Trials on Alzheimer’s Disease (CTAD) 2015 Conference in Barcelona, Spain. The data showed statistically significant improvements on exploratory clinical endpoints.”

“Normally we would not comment on management team expansion however we believe this is an important announcement as we see Anavex now building out the company’s infrastructure as 2-73 expands into a larger clinical footprint,” Kolbert added.

According to, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jason Kolbert has a total average return of -11.6% and a 32.2% success rate. Kolbert has a -4.8% average return when recommending AVXL, and is ranked #3634 out of 3642 analysts.

Cytori Therapeutics Inc

Additionally, Kolbert maintained a Buy rating on shares of Cytori, with a $5 price target, after the company announced data that supports a sustained benefit at two-years in the 12- patient SCLERADEC-I trial, which forms the basis of the current pivotal STAR trial in patients with hand dysfunction associated with scleroderma.

Kolbert stated, “We are encouraged by the strong results seen in the original trial showing a sustained benefit at two years. We see compelling value for patients and the potential for a premium pricing basis for the therapy.” The analyst added, “These data, along with other endpoints from the SCLERADEC-I trial, will be presented by Dr. Magalon at the 4th Systemic Sclerosis World Congress to be held in Lisbon, Portugal in February 2016.”

According to, Kolbert has a -42.1% average return when recommending CYTX. As of this writing, all the 4 analysts polled by TipRanks rate Cytori Therapeutics stock a Buy. With a return potential of 1051%, the stock’s consensus target price stands at $4.13.

Don’t be late to the party – Click Here to see what 4500 Wall Street Analysts say about your stocks.